Mirati (MRTX) reports third-quarter loss, beats revenue estimates

Mirati (MRTX) reported quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.27. That compares with a loss of $0.85 per share a year ago. The figure is adjusted for one-time items.

This quarterly report represents an earnings surprise of -8.66%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.21 per share when it actually produced a loss of $1.26, representing a surprise of -4.13%.

The company has failed to beat consensus earnings per share estimates over the past four quarters.

Mirati, a company that belongs to the Zacks Medical Biomedical and Genetics industry, posted revenues of $0.99 million for the quarter ended September 2019, surpassing the Zacks Consensus Estimate by 97.60% compared to zero a year earlier.

The sustainability of current share price movements based on recently released data and future earnings expectations will depend primarily on management’s commentary following the earnings conference call.

Year to date, Mirati shares are up about 122%, while the S&P 500 is up 21.2%.

What’s next for Mirati?

While Mirati has outperformed the market this year, the question that comes to investors’ minds is: what’s next for this stock?

There are no easy answers to this key question, but one reliable indicator that can help investors address this is the company’s earnings outlook. This includes not only the current consensus earnings expectations for the coming quarter(s), but also how those expectations have changed recently.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings report, the estimate revision trend for Mirati was mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. As such, the stock is expected to perform in line with the market in the near term. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the upcoming quarters and current fiscal year change in the coming days. The current consensus EPS estimate is -$1.38 on $0.70 million in revenue for the coming quarter and -$5.08 on $2.01 million in revenue for the current fiscal year.

Investors should be aware that the outlook for the industry can also have a significant impact on stock performance. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics currently ranks in the top 28% of the 250+ Zacks industries. Our research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click to get this free report

Mirati Therapeutics, Inc. (MRTX): Free Stock Analysis Report

To read this article on Zacks.com click here.